Novel Agents and Treatment Strategies for Relapsed/Refractory MF

Novel Agents and Treatment Strategies for Relapsed/Refractory MF
Novel Agents and Treatment Strategies for Relapsed/Refractory MF
CME, CPE
John Mascarenhas, MD
Release Date: July 14, 2021
Expiration Date: July 14, 2022

Join Dr. Mascarenhas as he discusses new and emerging treatment approaches for relapsed/refractory myelofibrosis (MF). Topics include a review of the COMFORT-1 and -2 and the JAKARTA2 trials of ruxolitinib and fedratinib, and recently released outcomes of trials evaluating investigational agents such as momelotinib, pacritinib, navitoclax, pelabresib, and imetelstat.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
Begin, Earn CreditView Only, No Credit